|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Far lateral lumbar disc herniation part 1: Imaging, neurophysiology and clinical features显示文摘Far lateral lumbar disc herniations(FLLDH)represent a separate category of disc pathology which includes both intraforaminal and extraforaminal lumbar disc herniations,that are characterized by a peculiar clinical presentation,diagnostic and treatment modalities as compared to the more frequent median and paramedian disc hernias.Surgical treatment often represents the only effective weapon for the cure of this disease and over the years different approaches have been developed that can reach the region of the foramen or external to it,with different degrees of invasiveness.The diagnosis is more demanding and still underestimated as it requires a more detailed knowledge in the spine anatomy and dedicated radiological studies.Computerized tomography and in particular magnetic resonance imaging are the appropriate tools for the diagnosis of FLLDH.Despite the widespread use of these diagnostic tests,many cases of FLLDH are overlooked due to insufficiently detailed radiological examinations or due to the execution of exams not focused to the foraminal or the extraforaminal region.Neurophysiological studies represent a valid aid in the diagnostic classification of this pathology and in some cases they can facilitate the differential diagnosis with other types of radiculopathies.In the present study,a comprehensive review of the clinical presentation,epidemiology,radiological study and the neurophysiological aspects is presented. | Luigi Valentino Berra Andrea Di Rita Federico Longhitano Enrico Mailland Paolo Reganati Alessandro Frati Antonio Santoro | 2021 | World Journal of Orthopedics2021，12，12： | 14 |
| 2 | Current approach in the treatment of hepatocellular ca显示文摘Hepatocellular carcinoma (HCC) is the most common malignant hepatobiliary disease; it is responsible for about 1 million deaths per year. Risk factors include hepatitis B and C, hepatic cirrhosis, including alcohol related hepatitis, metabolic and nutritional hepatic damage. The main modality of diffusion is intrahepatic in the natural course of the disease. There are two leading types of treatment: local and systemic. Surgical resection and liver transplantation constitute the most appropriate local treatments and are considered the only real possibility for recovery. Other local approaches include: radiofrequency ablation, percutaneous ethanol ablation, hepatic endoarterial chemoembolization and intrahepatic radiotherapy (SIRT: selective internal radiation therapy). These last treatments are used to control the disease when surgery or transplantation is not achievable; in some cases they are able to prolong survival while theyconstitute mainly a palliative treatment. Systemic treatments include: chemotherapy, immunological and hormonal therapies and, more recently, the introduction of new specific molecular target drugs. At the moment, in this group, the only drug that has given positive results during phase trials (SHARP study) is Sorafenib.Sorafenib represents the only primary systemic therapy that has demonstrated, unlike the other treatments previously described, an increase in survival rate in patients affected with advanced HCC. Currently, other studies are taking place that are further developing the potential of this drug. These studies, including phase trials, aredirected in order to test the activity and safety of new emerging drugs with targeted activity. Examples of these new agents are: Sunitinib, Gef itinib, Cetuximab, Bevacizumab and Erlotinib. | Luigi Rossi Federica Zoratto Anselmo Papa Francesca Iodice Marina Minozzi Luigi Frati Silverio Tomao | 2010 | World Journal of Gastrointestinal Oncology2010，2，9： | 11 |
| 3 | Multicentric glioma: our experience in 25 patients and critical review of the literature显示文摘 | Maurizio Salvati Emanuela Caroli Epimenio Ramundo Orlando Alessandro Frati Spartaco Artizzu Luigi Ferrante | 2003 | Neurosurgical Review2003，，4： | 1 |
| 4 | Serum HE4 levels combined with CE CT imaging improve the managementof monitoring women affected by epithelial ovarian cancer显示文摘 | Lucia Manganaro Simona Michienzi Valeria Vinci Renato Falzarano Matteo Saldari Teresa Granato Valentina Viggiani Luigi Frati Emanuela Anastasi | 2013 | Oncology Reports2013，，5： | 1 |
| 5 | HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma显示文摘 | Cecilia Midulla Lucia Manganaro Flavia Longo Valentina Viggiani Luigi Frati Teresa Granato Emanuela Anastasi | 2012 | Tumor Biology2012，，5： | 1 |
| 6 | Serum HE4 levels combined with CE CT imaging improve the managementof monitoring women affected by epithelial ovarian cancer显示文摘 | Lucia Manganaro Simona Michienzi Valeria Vinci Renato Falzarano Matteo Saldari Teresa Granato Valentina Viggiani Luigi Frati Emanuela Anastasi | 2013 | Oncology Reports2013，，： | 1 |
| 7 | Proximal aortic dissection with coronary malperfusion: Presentation, management, and outcome显示文摘 | Eugenio Neri Thomas Toscano Ugo Papalia Giacomo Frati Massimo Massetti Gianni Capannini Enrico Tucci Dimitri Buklas Luigi Muzzi Luca Oricchio Carlo Sassi | 2001 | The Journal of Thoracic and Cardiovascular Surgery2001，，3： | 1 |
| 8 | HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy显示文摘Dendritic cell(DC)-based immunotherapy is an attractive approach to induce long lasting antitumor effector cells aiming to control cancer progression. DC targeting is a critical step in the design of DC vaccines in order to optimize delivery and processing of the antigen, and several receptors have been characterized for this purpose. In this study, we employed the FcγRs to target DCs both in vitro and in vivo. We designed a recombinant molecule(HER2- Fc) composed of the immunogenic sequence of the human tumor-associated antigen HER2(aa 364–391) and the Fc domain of a human Ig G1. In a mouse model, HER2-Fc c DNA vaccination activated significant T cell-mediated immune responses towards HER2 peptide epitopes as detected by IFN-γ ELIspot and induced longer tumor latency as compared to Ctrl-Fc-vaccinated control mice. Human in vitro studies indicated that the recombinant HER2-Fc immunogen efficiently targeted human DCs through the FcγRs resulting in protein cross-processing and in the activation of autologous HER2-specific CD8+ T cells from breast cancer patients. | Ilaria Grazia Zizzari Filippo Veglia Federica Taurino Hassan Rahimi Elena Quaglino Francesca Belleudi Federica Riccardo Morena Antonilli Chiara Napoletano Filippo Bellati Pierluigi Benedetti-Panici Maria Rosaria Torrisi Luigi Frati Marianna Nuti Aurelia Rughetti | 2015 | 世界最新医学信息文摘2015，15，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员